ASHP + Partners Urge Congress Action on Drug Shortages

Share this content:
ASHP + Partners Urge Congress Action on Drug Shortages
ASHP + Partners Urge Congress Action on Drug Shortages

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- Congress has been urged to take immediate action in addressing the public health crisis associated with persistent shortages of critical medications, according to an announcement made at the mid-year clinical meeting and exhibition of the American Society of Health-System Pharmacists (ASHP), held from Dec. 3 to 7 in Orlando, Fla.

The ASHP, in collaboration with the American Hospital Association, the American Society of Anesthesiologists, the American Society of Clinical Oncology, the American Society of Parenteral and Enteral Nutrition, and the Institute for Safe Medication Practices, wrote a letter to representatives Morgan Griffith (R-Virginia) and Diana DeGette (D-Colorado) of the House Energy and Commerce Subcommittee on Oversight and Investigations.

The letter calls for improvement in the management of drug shortages and requests that Congress address the underlying reasons for this ongoing drug shortage problem. Specifically, the organizations provide a call to action for Congress to determine how manufacturers should handle disclosing drug shortages to the medical community. In addition, the letter asks Congress to examine whether sole-source products should be manufactured at multiple plants, whether there should be redundancy in production of critical products, and whether manufacturers should require development of a contingency plan for critical medications.

"The scarcity of information available on what drugs are manufactured at which plants and where those plants are located is extremely problematic," ASHP CEO Paul W. Abramowitz, Pharm.D., Sc.D., said in a statement. "This lack of transparency hinders health care organizations' efforts to take a proactive approach to drug shortages and puts patients at extreme risk for serious harm."

Letter
Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »